Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy

b1_banpc.jpg b1_banph.jpg

About Ribo

Global Leader and Pioneer in RNAi Technology and Oligonucleotide Drug Development

We are one of the earliest pioneers in oligonucleotide drugs, committed to advancing RNA interference (RNAi) technology and the industrialization of oligonucleotide drugs. We have established an oligonucleotide therapeutic platform that vertically integrates the complete set of technologies to support the full lifecycle from early R&D to commercialization. We have built a globally integrated drug development capability and a rich siRNA pipeline, covering cardiovascular, metabolic, renal, liver, and other diseases, especially chronic disease treatment. 

With a globally proprietary innovation R&D platform, we encompass the full lifecycle technology of oligonucleotide drugs from early research to commercialization, including drug delivery, chemical modification, multi-target drug development, model-informed drug development, pharmacology research and manufacturing. Among them, our proprietary liver-targeted delivery platform RiboGalSTARTM, has advanced several products into the clinical phase II stage, with excellent clinical validation of effectiveness and safety. Our partnership with one of the globally recognized pharmaceutical companies stands out as the sole platform-level collaboration between a China-based biotech company and a global MNC in the RNAi space, reflecting the high degree of recognition by multinational pharmaceutical companies of our R&D platform and scientific research strength. 

With a forward-looking global strategy, we have established R&D centers in Beijing and Suzhou, China, as well as in Europe. 

International R&D Center

Our international R&D center, Ribocure Pharmaceuticals AB, was established in February 2022 in Gothenburg, Sweden. Serving as our global hub for clinical and business development, Ribocure is staffed by a highly skilled team with international expertise and a strong track record in global clinical development. The center is equipped with advanced biology laboratories and a clinical Phase II trial facility, playing a leading role in driving clinical research and commercial advancement worldwide. 

b1_img01.jpg b1_img01_1.jpg

Management Team

  • b1_img02.png
    Dr. Zicai Liang

    Founding Chairman, CEO

  • b1_img03.png
    Dr. Liming Gan

    Co-CEO, President of Global Product R&D

  • b1_img04.png
    Dr. Hongyan Zhang

    Founding President

  • b1_img05.png
    Mr. Su Zhang

    Chief Financial Officer, Secretary of the Board, Company Secretary

  • 1.png
    Dr. Cheng (Charles) Tong

    Executive Vice President

  • 2.png
    Dr. Shan Gao

    Senior Vice President, Chief Scientific Officer

  • 3.png
    Dr. Anders Gabrielsen

    Vice President, Global Head of Clinical Development

  • 4.png
    Dr. John Taylor

    Vice President, Global Head of Business Development

b1_bg01.jpg

History

  • 2025

    January, 2025

    We achieved the first preclinical milestone under our collaboration with Boehringer Ingelheim.

  • 2025

    February, 2025

    We completed patient enrollment for RBD4059’s phase IIa clinical trial in patients with coronary artery disease in Sweden.

  • 2025

    February, 2025

    RBD2080 received the approval to initiate its phase I clinical trial in Australia.

  • 2025

    March, 2025

    We achieved the first two milestones to advance siRNA frug development with AI under our collaboration with Pheiron.

  • 2025

    May, 2025

    We completed patient enrollment for RBD7022's phase II clinical trial in patients under our collaboration with Qilu Pharmaceutical.

  • 2024

    January, 2024

    We collaborated with Boehringer Ingelheim to develop new treatments for people with liver diseases in the NASH/MASH space.

  • 2024

    January, 2024

    RBD1016’s phase II global MRCT in CHB patients expanded to Hong Kong.

  • 2024

    April, 2024

    RBD1016’s phase IIa clinical trial in CHD patients was approved in Sweden.

  • 2024

    April, 2024

    RBD4059’s phase I clinical trial in Australia was completed.

  • 2024

    May, 2024

    RBD4059’s phase IIa clinical trial in patients with coronary artery disease approved by EU.

  • 2024

    September, 2024

    RBD7007 received CTA approval from EMA to initiate its phase I clinical trial.

  • 2024

    September, 2024

    We have entered into a strategic partnership with PHEIRON for AI-assisted drug development of RNA therapeutics.

  • 2024

    October, 2024

    RBD1016 RBD1016’s phase II clinical trial in CHB patients was approved in China.

  • 2023

    February, 2023

    RBD4059’s phase I clinical trial receives HREC approval in Australia.

  • 2023

    April, 2023

    Patents for RiboGalSTARTM delivery technology and RSC2.0 siRNA chemical modification technology platform licensed in major jurisdictions.

  • 2023

    May, 2023

    RBD1016’s phase II clinical trial was approved in Sweden.

  • 2023

    June, 2023

    We updated Study Data on siRNA Products for the Treatment of NASH (R0737072) and Hepatitis B (RBD1016) Presented at EASL 2023.

  • 2023

    October, 2023

    We completed RBD1016’s phase Ib clinical trial in patients with CHB in Hong Kong.

  • 2023

    December, 2023

    We granted Qilu Pharmaceutical Co., Ltd. the rights to develop, manufacture and commercialize RBD7022 in Greater China region.

  • 2022

    January, 2022

    RBD1016 has completed the safety and pharmacokinetic evaluation clinical study in Australian Healthy Subjects.

  • 2022

    February, 2022

    We established Ribocure AB in Sweden as our international R&D center.

  • 2022

    February,2022

    We completed two phase II clinical trials of antisense oligonucleotide for Type 2 Diabetes.

  • 2022

    July,2022

    We completed Series E1 Financing and raised $40 million.

  • 2022

    September,2022

    RBD7022 for treating hyperlipidemia, has been approved for its first in human clinical trial in China.

  • 2022

    October,2022

    We successfully passed the EU GMP Audit.

  • 2022

    November,2022

    The first-in-human clinical trial of RBD5044 for the treatment of hyperlipidemia was initiated in Australia.

  • 2021

    February,2021

    RBD1016’s phase Ia clinical trial was initiated.

  • 2021

    April, 2021

    We completed the enrollment of the first patient in the Chinese Phase IIa clinical trial of our antisense oligonucleotide, ISIS560131 injection.

  • 2020

    March, 2020

    We completed Series C2 financing and raised RMB 470 million.

  • 2020

    August, 2020

    We received the approval of clinical trials for new drug treatment of metastatic prostate cancer.

  • 2020

    September, 2020

    We completed Series C+ financing and raised RMB 250 million.

  • 2019

    January, 2019

    We received the approval of clinical application for new oligonucleotide therapeutics in the treatment of type 2 diabetes.

  • 2019

    December, 2019

    We completed Series C1 financing and raised RMB 203 million.

  • 2017

    April, 2017

    We launched a strategic collaboration with global oligonucleotide pharmaceutical giant, Ionis, USA.

  • 2017

    April, 2017

    We completed Series B financing and raised RMB 270 million.

  • 2016

    January, 2016

    We completed Series A financing and raised RMB 125 million.

  • 2015

    December, 2015

    RBD1007 received IND approval from NMPA, marking the first oligonucleotide drug approved to enter clinical stage in China.

  • 2010

    December, 2010

    We completed ISO 9001:2008 quality management system accreditation.

  • 2008

    April, 2008

    We successfully hosted the first RNAi China conference.

  • 2007

    January, 2007

    Our company was established as a limited liability company in Kunshan, Jiangsu Province.

  • 2007

    April, 2007

    Our R&D center was established in Zhongguancun, Beijing.

  • 2025

  • 2024

  • 2023

  • 2022

  • 2021

  • 2020

  • 2019

  • 2017

  • 2016

  • 2015

  • 2010

  • 2008

  • 2007

Our Values

We are guided by scientific rigor and uphold core values of pioneering innovation, efficiency, collaboration, integrity, and responsibility. 

With commitment to patient-centric R&D, we drive transformative progress in global health through oligonucleotide therapeutics. 

b1_img06.jpg b1_img06_1.jpg
We are here and look forward to communicating with you